NIKKEI 225
39,583.08 +241.58 (+0.61%) HANG SENG
17,718.61 +2.11 (+0.01%) CRUDE OIL
81.56 +0.02 (+0.02%) GOLD FUTURES
2,335.10 -4.50 (-0.19%) DOW
39,118.86 -45.24 (-0.12%) Bitcoin GBP
49,583.31 +1,460.99 (+3.04%)
ORMP Jul 2024 2.500 call
| Previous close | 0.3000 |
| Open | 0.2500 |
| Bid | 0.2500 |
| Ask | 2.7000 |
| Strike | 2.50 |
| Expiry date | 2024-07-19 |
| Day's range | 0.2500 - 0.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 154 |
PR NewswireOramed Letter to Shareholders
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed") (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron.
- PR Newswire
Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (the "Company") (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced today that its Board of Directors has authorized a common stock repurchase plan allowing for the buy-back of up to $20,000,000 in maximum value of its common stock through open market purchases, privately-negotiated transactions, or otherwise in compliance with Rule 10b-18 under the Securities
Simply Wall St.Oramed Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)
Oramed Pharmaceuticals ( NASDAQ:ORMP ) First Quarter 2024 Results Key Financial Results Net income: US$1.54m (up from...
